Innovative Cancer Treatments Peregrine Pharmaceuticals is actively developing novel monoclonal antibodies, with its lead candidate bavituximab in Phase III trials for second-line non-small cell lung cancer and exploring treatments for multiple other cancer types, indicating a strong focus on targeted immunotherapies and diagnostics.

Integrated Manufacturing Capabilities With in-house cGMP manufacturing through its subsidiary Avid Bioservices, the company can provide high-quality biologics development and manufacturing services, presenting opportunities for partnerships and supply chain collaborations with biotech firms seeking reliable production partners.

Research and Development Focus Peregrine’s commitment to advancing immunotherapy and cancer imaging solutions offers potential for collaborations with technology providers and research organizations aiming to expand innovative cancer detection and treatment modalities.

Leadership and Strategic Growth Recent appointments of experienced executives and board members suggest strategic efforts to strengthen leadership, creating avenues for engagement with organizations looking to partner with or invest in pioneering biotech companies.

Market Position and Funding While revenue is in the $10M-$25M range, Peregrine’s focus on late-stage clinical trials and manufacturing positions it as a valuable partner for pharmaceutical companies and contract manufacturing clients seeking high-quality, specialized biopharmaceutical production.